Last updated: July 27, 2026
Executive summary
- Drug: YUPELRI (revefenacin) for chronic obstructive pulmonary disease (COPD).
- Regulatory: Approved by FDA for once-daily inhalation via nebulization (maintenance treatment of COPD, including chronic bronchitis and emphysema).
- Commercial trajectory: Growth since launch has been driven by the shift toward maintenance LAMA monotherapy and LAMA-heavy COPD regimens; market expansion depends on payer uptake, inhaler/nebulizer convenience perceptions, and competitive pressure from LAMA/LABA fixed-dose products.
- Pipeline and competitive risk: Near-term market share risk is primarily from other LAMAs (including once-daily options) and dual bronchodilator combinations; patent exclusivity and formulation protections determine generic erosion timing and entry barriers.
- Patent-driven outlook: YUPELRI’s ability to sustain branded revenue hinges on the remaining term of composition, method-of-use, and formulation/particle-engineering IP, plus any Paragraph IV litigation outcomes for potential generics.
What is YUPELRI (revefenacin) and what clinical-trial evidence supports it?
Direct answer: YUPELRI is a long-acting muscarinic antagonist (LAMA) approved for maintenance treatment of COPD. Its pivotal program established improvements in lung function (FEV1) and symptom/health-status outcomes compared with placebo.
Key clinical endpoints used in the pivotal program
- Primary pharmacodynamic endpoint: trough and/or serial forced expiratory volume in 1 second (FEV1) following repeated dosing.
- Symptom and health status: transitions and patient-reported outcomes in COPD maintenance settings.
- Exacerbations: risk reduction and/or time-to-first exacerbation analyses where powering allowed.
Trial design characteristics that shaped uptake
- Maintenance dosing: once-daily bronchodilation intended for day-to-day symptom control.
- Comparator structure: placebo and/or active respiratory standard comparators in registration-grade designs.
- Relevance to real-world prescribing: LAMA monotherapy as an early-line option when dual therapy is not yet used.
Clinical trial registration and FDA approval basis for revefenacin is described in FDA review and label documentation. (See FDA references in the citation list.)
What are the latest YUPELRI clinical trial updates and ongoing studies?
Direct answer: As of the most recent public FDA labeling and major registries, the revealed focus for revefenacin has been on COPD maintenance efficacy/safety and position within broader bronchodilator strategies rather than a new indication expansion that would materially reset exclusivity.
What typically drives the “clinical update” narrative for YUPELRI
- Postmarketing safety surveillance: COPD bronchodilator class monitoring (cardiovascular, anticholinergic class events).
- Formulation/handling optimization: usability and nebulization performance in routine care.
- Subgroup confirmation: older populations, baseline symptom severity bands, and inhalation technique sensitivities (even though nebulization reduces technique variability versus dry powder inhalers).
- Combination strategy studies: assessing performance in multi-bronchodilator regimens (often more common for inhaled combinations than LAMA monotherapy).
For a market-facing decision, the key question is whether any ongoing study creates a new exclusivity hook (new indication, new dosage, or new formulation pathway). That type of “reset” is not established by the public label history described below.
What patents protect YUPELRI (revefenacin) and how strong is the patent estate?
Direct answer: YUPELRI’s protections typically span composition-of-matter, formulation/manufacturing of nebulizable solution, and potentially method-of-use for COPD maintenance. The strength for preventing generic entry depends on how many independent claims remain unexpired or unchallenged, and whether Orange Book entries include formulation and use claims that can survive.
Patent estate map to assess generic entry barriers
A practical estate review for YUPELRI usually includes:
- Composition claims covering revefenacin and/or chemical intermediates (earliest-filing anchors).
- Formulation claims addressing nebulization performance:
- solution stability, viscosity targets, surfactant/tonicity strategy
- particle/solubilization considerations where applicable
- Method-of-use claims:
- once-daily COPD maintenance
- patient selection and/or administration regimen
Why formulation patents matter for nebulized LAMA products
- Even when composition claims expire, generics can be blocked by formulation-specific claim scope that ties to:
- nebulizer compatibility
- dosing volume and aerosol performance metrics
- stability and shelf-life characteristics that affect approved labeling
What is the Orange Book status of YUPELRI (revefenacin)?
Direct answer: Orange Book status determines whether generics can file ANDA Section IV (Paragraph IV) against specific listed patents.
How to interpret the Orange Book for risk
- Listed patents are typically categorized as:
- Drug substance
- Drug product (formulation)
- Use (method)
- Generic filing risk rises when:
- multiple listed patents expire
- remaining patents are narrow and easily designed around
- no active stay is in place from an infringement suit
A complete Orange Book listing requires the specific Orange Book entry set for the exact NDA strength and dosage form. Without that entry set in the record here, a precise patent-by-patent status cannot be stated.
When does YUPELRI lose exclusivity, and what are the generic launch risks?
Direct answer: Exclusivity timing is governed by the latest combination of:
- patent expirations on Orange Book-listed claims
- regulatory exclusivities (new chemical entity and/or other statutory exclusivity)
- any litigation-driven stays from Paragraph IV challenges
Generic entry scenario framework (what drives launch timing)
- First eligible ANDA:
- depends on the earliest expiration of the Orange Book patents mapped to the filing
- 180-day exclusivity:
- can be triggered by the first Paragraph IV filer that is not subsequently disqualified
- Court outcomes:
- an infringement judgment for the brand pushes launches out until appellate exhaustion or settlement terms
A quantified “date of generic eligibility” cannot be provided without a specific Orange Book patent list and their expiration/terminal disclaimers.
What Paragraph IV challenges or patent litigation affects YUPELRI?
Direct answer: Generic erosion risk is driven by whether any ANDA filers have submitted Paragraph IV certifications and whether the brand obtained an injunction or a settlement that delays entry.
Litigation dynamics that matter to investors
- Automatic 30-month stay (when triggered) can delay FDA approval pending litigation.
- Settlement agreements often include:
- “no launch until” dates
- defined at-risk launch windows contingent on patent challenges
- Design-around:
- formulation and nebulization-performance constraints can block “at-risk” commercialization even after some claim expirations.
Litigation outcomes require specific dockets or press releases tied to the NDA’s Orange Book patents, which are not provided in the available record here.
How does YUPELRI compare with other LAMAs and COPD maintenance options (market share and payer positioning)?
Direct answer: YUPELRI is positioned against once-daily LAMA therapies and against dual bronchodilator regimens that increasingly dominate maintenance COPD formularies.
Competitive set for market mapping
- Other LAMAs: once-daily and twice-daily options depending on molecule class.
- LAMA/LABA fixed combinations: commonly preferred as disease burden and symptom control needs increase.
- Escalation pathways:
- LAMA monotherapy for mild-to-moderate symptoms and early maintenance
- dual therapy for persistent symptoms or higher exacerbation risk
- triple therapy when dual therapy is insufficient (where applicable)
Nebulization vs inhaler dynamics
- Nebulizers can reduce “inhaler technique” variability, which can matter for:
- older patients
- patients with tremor, dexterity constraints, or poor inhalation coordination
- On the payer side, the tradeoff is often:
- device and administration cost vs adherence benefits
Which companies are likely competing hardest with YUPELRI, and what are the commercial threats?
Direct answer: The biggest branded threats typically come from:
- LAMA incumbents with strong contracting
- LAMA/LABA combinations with favorable formulary placement
- pharmacy benefit manager (PBM) incentives that steer utilization toward preferred products
Commercial pressure points that reduce branded growth
- Formulary tier placement: moving YUPELRI from preferred to non-preferred tier can materially reduce net sales.
- Step edits: requiring trials of alternative bronchodilators before coverage.
- Contracting: rebates and outcomes-based agreements may shift patient flows to competing products.
What revenue exposure does YUPELRI face from generic entry, and what is the likely uptake curve?
Direct answer: Revenue exposure is binary on legal timelines: generic entry can produce rapid price compression, followed by a slower volume-driven stabilization if brand persists through payer mix and institutional use.
Typical brand erosion pattern in inhaled maintenance categories
- Launch quarter: steep net price declines due to acquisition of market share by first entrants.
- Year 1-2: volume migration to generics if formulary rules favor low-cost options.
- Long-run: brand retention often depends on:
- patient subpopulation suitability for nebulization
- adherence and satisfaction differentials
- contract-based reimbursement
A specific revenue model requires the current baseline revenue and assumed generic penetration, neither of which is available in the provided record.
YUPELRI market projection 2026-2035: base, upside, and downside scenarios
Direct answer: A credible projection must tie to (1) COPD prevalence and severity mix, (2) formulary placement of LAMA monotherapies vs combinations, and (3) exclusivity/generic timing. Without current-year net sales and patent-date specifics in the record, only scenario structure can be stated, not quantified figures.
Scenario logic used for inhaled COPD LAMA valuation
- Base case drivers
- gradual market expansion with moderate class competition
- limited substitution away from nebulized regimens
- no major exclusivity disruption in the near term
- Downside case drivers
- earlier generic/authorized generic pressure
- stronger preferred positioning for LAMA/LABA fixed products
- step edits that reduce monotherapy conversion
- Upside case drivers
- favorable contracting and persistency improvements
- demographic tailwinds in older COPD cohorts
- durability of differentiated nebulization adherence benefits
Key inputs to build an investment-grade YUPELRI forecast
Direct answer: Forecast quality depends on patent timelines and payer channel mechanics.
Regulatory and labeling inputs
- FDA-approved indication and dosing (maintenance COPD, once-daily nebulization).
- Safety signals in labeling that can influence restricted-use policies.
Competitive and payer inputs
- National formulary coverage and placement (preferred vs non-preferred).
- PBM incentives and step therapy requirements for LAMA monotherapy.
IP and entry inputs
- Orange Book listed patents and expiration/terminal disclaimers.
- Pending Paragraph IV certifications and any litigation stays or settlements.
Key Takeaways
- YUPELRI (revefenacin) is a COPD maintenance LAMA with clinical efficacy centered on lung function and maintenance symptom control.
- The commercial outlook is driven less by new clinical expansion and more by formulary contracting and competition from LAMA/LABA combinations.
- Generic entry risk is determined by Orange Book-listed patents and any Paragraph IV litigation outcomes.
- A quantified 2026-2035 projection requires current net sales baseline, updated FDA/Orange Book patent details, and confirmed litigation status, which are not provided in the available record here.
FAQs
- Does YUPELRI qualify for Medicaid preferred status and how does formulary placement affect uptake?
- Can generics of revefenacin be substituted for YUPELRI without triggering formulation-specific barriers?
- What real-world factors improve persistence with nebulized LAMA therapy versus inhaler-based LAMAs?
- How do LAMA/LABA combination therapies change the conversion rate from LAMA monotherapy in COPD?
- What FDA regulatory pathway would a generic revefenacin ANDA use, and what certifications are typically required?
References (APA)
- U.S. Food and Drug Administration. (n.d.). YUPELRI (revefenacin) prescribing information. FDA. https://www.accessdata.fda.gov/
- U.S. Food and Drug Administration. (n.d.). Drug Trials Snapshots: Revefenacin. FDA. https://www.fda.gov/
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
